artemether

O-methyldihydroartemisinine

CAS: 71939-51-0 C16 H26 O5 MW: 298.37922000

Identification

Nameartemether
CAS Number71939-51-0
FDA UNII111W6L37CC
Molecular FormulaC16 H26 O5
Molecular Weight298.37922000
Nikkaji NumberJ841.010K

Regulatory

Physical Properties

Appearance white crystalline powder (est)
Assay 95.00 to 100.00
Food Chemicals Codex Listed No
Melting Point 86.00 °C. @ 760.00 mm Hg (est)
Boiling Point 357.46 °C. @ 760.00 mm Hg (est)
Vapor Pressure 4.000000 mmHg @ 25.00 °C. (est)
Flash Point 285.00 °F. TCC ( 140.50 °C. ) (est)
logP (o/w) 2.820 (est)
Soluble in water, 12.13 mg/L @ 25 °C (est)

No sensory data available

Safety Information

Oral/Parenteral ToxicityNot determined
Dermal ToxicityNot determined
Inhalation ToxicityNot determined

GHS Classification

['GHS Classification in accordance with 29 CFR 1910 (OSHA HCS)', 'GHS Label elements, including precautionary statements']

Safety in Use

Categorypharmaceuticals / chemical synthisis
Recommendation for artemether usage levels up tonot for fragrance use.
Recommendation for artemether flavor usage levels up tonot for flavor use.

BOC Sciences

Best of Chemicals Supplier

Quality supplier of research chemicals and biochemicals including inhibitors, building blocks, GMP Products, impurities and metabolites, APIs for Veterinary, Natural Compounds, ADCs, Stem Cell Molecul...

View All Website 1-631-485-4226 account@bocsci.com

Potential Uses

None Found

Natural Occurrence

not found in nature

Synonyms

(+)-alpha- artemether alpha- artemether alpha- dihydroartemisinin methyl ether 3,12- epoxy-12H-pyrano(4,3-j)-1,2-benzodioxepin, decahydro-10-methoxy-3,6,9-trimethyl-, (3R,5aS,6R,8aS,9R,10R,12R,12aR)- 3,12- epoxy-12H-pyrano[4,3-j]-1,2-benzodioxepin, decahydro-10-methoxy-3,6,9-trimethyl-, (3R,5aS,6R,8aS,9R,10R,12R,12aR)- ortho- methyl dihydroartemisinine O- methyldihydroartemisinine PubMed: Pharmacokinetics of a novel sublingual spray formulation of the antimalarial drug artemether in African children with malaria. PubMed: A comparative study on the impact of two artemisinin derivatives, artemether and artesunate, on the female reproductive system of Fasciola hepatica. PubMed: Tailoring a Pediatric Formulation of Artemether-Lumefantrine for Treatment of Plasmodium falciparum Malaria. PubMed: Integration of novel low-cost colorimetric, laser photometric, and visual fluorescent techniques for rapid identification of falsified medicines in resource-poor areas: application to artemether-lumefantrine. PubMed: Artemether-lumefantrine: an option for malaria. PubMed: Optimizing the programmatic deployment of the anti-malarials artemether-lumefantrine and dihydroartemisinin-piperaquine using pharmacological modelling. PubMed: Comparison of bioavailability between the most available generic tablet formulation containing artemether and lumefantrine on the Tanzanian market and the innovator's product. PubMed: Use of artemether-lumefantrine to treat malaria during pregnancy: what do we know and need to know? PubMed: Population-wide malaria testing and treatment with rapid diagnostic tests and artemether-lumefantrine in southern Zambia: a community randomized step-wedge control trial design. PubMed: Efficacy of artesunate-amodiaquine and artemether-lumefantrine fixed-dose combinations for the treatment of uncomplicated Plasmodium falciparum malaria among children aged six to 59 months in Nimba County, Liberia: an open-label randomized non-inferiority trial. PubMed: Efficacy of artemether-lumefantrine in area of high malaria endemicity in India and its correlation with blood concentration of lumefantrine. PubMed: Early clinical development of artemether-lumefantrine dispersible tablet: palatability of three flavours and bioavailability in healthy subjects. PubMed: Monitoring of artemisinin, dihydroartemisinin, and artemether in environmental matrices using high-performance liquid chromatography-tandem mass spectrometry (LC-MS/MS). PubMed: Implementation of artemether-lumefantrine treatment policy for malaria at health facilities in Tanzania. PubMed: The effect of food consumption on lumefantrine bioavailability in African children receiving artemether-lumefantrine crushed or dispersible tablets (Coartem) for acute uncomplicated Plasmodium falciparum malaria. PubMed: Rational dispensing and use of artemether-lumefantrine during pregnancy in Dar es Salaam, Tanzania. PubMed: Comparable lumefantrine oral bioavailability when co-administered with oil-fortified maize porridge or milk in healthy volunteers. PubMed: Changes in the visceral functions of Plasmodium berghei-infected and -uninfected rats following administration of artemether. PubMed: Adherence to and acceptability of artemether-lumefantrine as first-line anti-malarial treatment: evidence from a rural community in Tanzania. PubMed: Evaluation of the developmental toxicity of artemether during different phases of rat pregnancy. PubMed: Dispersible formulation of artemether/lumefantrine: specifically developed for infants and young children. PubMed: First case of treatment failure of artemether-lumefantrine in a Japanese traveler with imported falciparum malaria. PubMed: Pharmacokinetic interaction trial between co-artemether and mefloquine. PubMed: The effect of grapefruit juice on the time-dependent decline of artemether plasma levels in healthy subjects. PubMed: Efficacy of artemether-lumefantrine for the treatment of uncomplicated falciparum malaria in northwest Cambodia. PubMed: Pharmacokinetics and electrocardiographic pharmacodynamics of artemether-lumefantrine (Riamet) with concomitant administration of ketoconazole in healthy subjects. PubMed: Effect of artesunate and artemether against Clonorchis sinensis and Opisthorchis viverrini in rodent models. PubMed: Effect of artemether alone and in combination with grapefruit juice on hepatic drug-metabolising enzymes and biochemical aspects in experimental Schistosoma mansoni. PubMed: Supervised versus unsupervised intake of six-dose artemether-lumefantrine for treatment of acute, uncomplicated Plasmodium falciparum malaria in Mbarara, Uganda: a randomised trial. PubMed: Clinical pharmacokinetics and pharmacodynamics and pharmacodynamics of artemether-lumefantrine. PubMed: Artemether + lumefantrine: new drug. An alternative to atovaquone + proguanil. PubMed: Artemether-lumefantrine versus dihydroartemisinin-piperaquine for treating uncomplicated malaria: a randomized trial to guide policy in Uganda. PubMed: Pharmacokinetic study of artemether-lumefantrine given once daily for the treatment of uncomplicated multidrug-resistant falciparum malaria. PubMed: The content of African diets is adequate to achieve optimal efficacy with fixed-dose artemether-lumefantrine: a review of the evidence. PubMed: Understanding the pharmacokinetics of Coartem. PubMed: Factors affecting availability of essential medicines among community health workers in Ethiopia, Malawi, and Rwanda: solving the last mile puzzle. PubMed: Experience With the Priority Review Voucher Program for Drug Development. PubMed: Studies of the neurotoxicity of oral artemisinin derivatives in mice. PubMed: A qualitative study of perceptions of a mass test and treat campaign in Southern Zambia and potential barriers to effectiveness. PubMed: Management of imported malaria in Europe. PubMed: Development of simplified HPLC methods for the detection of counterfeit antimalarials in resource-restraint environments. PubMed: Malaria: severe, life-threatening. PubMed: Awareness of anti-malarial policy and malaria treatment practices of patent medicine vendors in three Nigerian states. PubMed: Mechanism-based design of parasite-targeted artemisinin derivatives: synthesis and antimalarial activity of new diamine containing analogues. PubMed: Pharmacokinetics and pharmacodynamics of lumefantrine (benflumetol) in acute falciparum malaria. PubMed: How much fat is necessary to optimize lumefantrine oral bioavailability? PubMed: [The treatment of falciparum malaria]. PubMed: Artemisinin-based combination therapies for uncomplicated malaria. PubMed: First artemisinin-based antimalarial combination approved for U.S. market. PubMed: Artemisinins and synthetic trioxolanes in the treatment of helminth infections. PubMed: [Mechanism of action of antimalarials. Value of combined atovaquone/proguanil]. PubMed: Antiparasitic agents. PubMed: Malaria: severe, life-threatening. PubMed: Malaria: uncomplicated, caused by Plasmodium falciparum. PubMed: Arteether toxicokinetics and pharmacokinetics in rats after 25 mg/kg/day single and multiple doses. PubMed: FDA launches priority vouchers for neglected-disease drugs.